Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI filing briefs · archive

8-K filings in May 2023, explained

17 material Form 8-K filings that 16 companies we cover made with the SEC in May 2023, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).

Clear

1 of 17 briefs matches

newest first · times in ET
CMMBChemomab Therapeutics Ltd. May 11, 6:10 AM ET

Chemomab Q1 2023 net loss widens to $8.8 million; cash runway extended to H1 2024

Negative earnings Written later 2.02

Chemomab Therapeutics reported a first-quarter 2023 net loss of $8.8 million, up from $5.1 million a year earlier, driven mainly by higher research and development spending. Cash, cash equivalents and short-term deposits fell to $32.8 million at March 31, 2023, from $39.9 million at December 31, 2022, and the company said its estimated cash runway now extends through the first half of 2024.

  • Net loss was $8.8 million, or about $0.04 per share, versus $5.1 million, or about $0.02 per share, in the first quarter of 2022.
  • R&D expenses were $6.9 million versus $2.7 million a year earlier, primarily due to increased clinical and preclinical activities.
  • Cash, cash equivalents and short-term bank deposits were $32.8 million at March 31, 2023, compared with $39.9 million at December 31, 2022.
  • Estimated cash runway was extended through the first half of 2024; the CM-101 Phase 2 PSC trial top-line data are expected in the second half of 2024.
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.

Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.